BlinkLab's ADHD European Case-Control Study Achieves High Sensitivity, Specificity Results; Shares Jump 10%

MT Newswires Live08-05

BlinkLab (ASX:BB1) said its European case-control study of smartphone-based digital neurobehavioral biomarkers in children between the ages of 6 years and 17 years, both with and without attention-deficit/hyperactivity disorder (ADHD), achieved sensitivity of 82% and specificity of 83%, relative to its clinical diagnostic reference standard, according to a Wednesday Australian bourse filing.

The participants were recruited across multiple Mental Care Group centers in the Netherlands, as well as from the general community, and completed smartphone-based assessments, which were designed to collect digital neurobehavioral biomarkers, the firm said.

The firm's machine learning Dx2 algorithm correctly identified 82% of participants in the group with a confirmed clinical diagnosis of ADHD as exhibiting the target neurobehavioral features associated with the disorder, and correctly classified 83% of children in the comparison group, per the filing.

Its shares jumped nearly 10% in recent trading on Wednesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2657951555?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 08:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657951555","market":"sh","top_or_hot":-1,"title":"BlinkLab's ADHD European Case-Control Study Achieves High Sensitivity, Specificity Results; Shares Jump 10%","media":"MT Newswires Live","content":"<html><body><p> BlinkLab (ASX:BB1) said its European case-control study of smartphone-based digital neurobehavioral biomarkers in children between the ages of 6 years and 17 years, both with and without attention-deficit/hyperactivity disorder (ADHD), achieved sensitivity of 82% and specificity of 83%, relative to its clinical diagnostic reference standard, according to a Wednesday Australian bourse filing.</p><p>The participants were recruited across multiple Mental Care Group centers in the Netherlands, as well as from the general community, and completed smartphone-based assessments, which were designed to collect digital neurobehavioral biomarkers, the firm said.</p><p>The firm's machine learning Dx2 algorithm correctly identified 82% of participants in the group with a confirmed clinical diagnosis of ADHD as exhibiting the target neurobehavioral features associated with the disorder, and correctly classified 83% of children in the comparison group, per the filing.</p><p>Its shares jumped nearly 10% in recent trading on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BlinkLab's ADHD European Case-Control Study Achieves High Sensitivity, Specificity Results; Shares Jump 10%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBlinkLab's ADHD European Case-Control Study Achieves High Sensitivity, Specificity Results; Shares Jump 10%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-05 08:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> BlinkLab (ASX:BB1) said its European case-control study of smartphone-based digital neurobehavioral biomarkers in children between the ages of 6 years and 17 years, both with and without attention-deficit/hyperactivity disorder (ADHD), achieved sensitivity of 82% and specificity of 83%, relative to its clinical diagnostic reference standard, according to a Wednesday Australian bourse filing.</p><p>The participants were recruited across multiple Mental Care Group centers in the Netherlands, as well as from the general community, and completed smartphone-based assessments, which were designed to collect digital neurobehavioral biomarkers, the firm said.</p><p>The firm's machine learning Dx2 algorithm correctly identified 82% of participants in the group with a confirmed clinical diagnosis of ADHD as exhibiting the target neurobehavioral features associated with the disorder, and correctly classified 83% of children in the comparison group, per the filing.</p><p>Its shares jumped nearly 10% in recent trading on Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2657951555","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2657951555","pubTimestamp":1785890370,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BlinkLab (ASX:BB1) said its European case-control study of smartphone-based digital neurobehavioral biomarkers in children between the ages of 6 years and 17 years, both with and without attention-def","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","EPV":"ProShares UltraShort MSCI Europe","BB1.AU":"Blinklab Ltd","BK7094":"医疗保健技术","ADHD":"Alcobra Ltd.","ABVC":"ABVC BioPharma, Inc."},"translate_title":"BlinkLab的ADHD欧洲病例对照研究取得了高灵敏度、特异性的结果；股价上涨 10%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABVC":1.5,"BB1.AU":1,"EPV":1.5,"ADHD":1.5},"content_text":"BlinkLab (ASX:BB1) said its European case-control study of smartphone-based digital neurobehavioral biomarkers in children between the ages of 6 years and 17 years, both with and without attention-deficit/hyperactivity disorder (ADHD), achieved sensitivity of 82% and specificity of 83%, relative to its clinical diagnostic reference standard, according to a Wednesday Australian bourse filing.The participants were recruited across multiple Mental Care Group centers in the Netherlands, as well as from the general community, and completed smartphone-based assessments, which were designed to collect digital neurobehavioral biomarkers, the firm said.The firm's machine learning Dx2 algorithm correctly identified 82% of participants in the group with a confirmed clinical diagnosis of ADHD as exhibiting the target neurobehavioral features associated with the disorder, and correctly classified 83% of children in the comparison group, per the filing.Its shares jumped nearly 10% in recent trading on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2657951555","isCrawlerRequest":true}